Gentium SpA (GENT -5.3%) trades lower today - albeit up significantly from the 16% pounding it took just prior to the open - after the company said the European Medicines Agency's Committee for Medicinal Products for Human Use rejected Defibrotide, its treatment for hepatic veno-occlusive disease. GENT will appeal the EMA's decision.